Lieping Chen, MD, PhD, has been elected as a Fellow of the American Association for Cancer Research (AACR) Academy.
- July 08, 2020
Yale Cancer Center researchers were awarded a $11 million grant renewal from the National Institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer.
- March 16, 2020
In a landmark moment in cancer research, Yung-Chi Cheng and research partners are launching the first international clinical trial for a botanical drug, YIV-906. The trial involves patients with liver cancer and hepatitis B.
- February 28, 2020
The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest breakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.
- January 22, 2020
Yale Cancer Center (YCC) held its annual Conclave and award ceremony at the New Haven Country Club on Monday, January 13.
- December 11, 2019
The study results help explain the origins of lupus and suggest novel ways researchers might be able to provide much needed new therapy to treat the disease, the scientists said.
- October 04, 2018
Yale Cancer Center (YCC) scientist Lieping Chen, M.D., Ph.D., who pioneered cancer immunotherapy studies targeting the PD-1/PD-L1 pathway, is suggesting a dramatically different paradigm for research in the field.
- October 04, 2018
The Nobel Prize was awarded Monday for cancer immunology. The 2018 Nobel laureates James Allison and Tasuku Honjo found proteins known as immune checkpoints that can stop T-cells, causing them to pass over a cancer cell instead of attacking it. Checkpoint inhibitors drastically transformed the field of cancer immunology said Mario Sznol, co-director of the Cancer Immunology Program at YCC. He praised the decision to award Allison and Honjo, but said many others also deserved recognition. “One who didn’t get the Nobel Prize but made a major, major contribution to understanding this pathway and its role in the treatment of cancer is Dr. Lieping Chen, who’s here at Yale, and as far as I’m concerned, Dr. Chen also deserves part of the Nobel Prize.”
- August 30, 2018Source: New Haven Register
Smilow and the Yale Cancer Center's major Breakthroughs: From the first physician-in-chief of the Smilow Cancer Hospital to building translational bridges between clinical trials and basic science
- April 26, 2018Source: OncLive
Lieping Chen, MD, PhD, co-director of the Cancer Immunology Program at Yale Cancer Center, has been selected as one of this year's Giants in Cancer Care by OncLive. Dr. Chen joins 21 respected healthcare professionals who are advancing the field of oncology by their contributions in research and clinical practice. The winners will be celebrated on May 31st at a ceremony in Chicago. Nominated by the oncology community, all finalists are selected by an elite seven-member advisory board of world-renowned oncologists. The finalists in each category are then voted on by a 100-plus member selection committee comprising the nation's leading physicians in the oncology space.